{"gene":"PIM3","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":2006,"finding":"PIM3 serine/threonine kinase phosphorylates the pro-apoptotic protein BAD at Ser112 (but not Ser136) in human pancreatic cancer cells, inactivating BAD and preventing apoptosis; PIM3 knockdown reduced pBAD(Ser112) and Bcl-XL expression and promoted apoptosis.","method":"shRNA knockdown, Western blot for pBAD(Ser112) and pBAD(Ser136), flow cytometry for apoptosis","journal":"Cancer Research","confidence":"High","confidence_rationale":"Tier 2 / Strong — replicated across multiple cancer types (pancreas, colon, liver) by multiple labs using KD with defined molecular readout (pBAD Ser112)","pmids":["16818649"],"is_preprint":false},{"year":2007,"finding":"PIM3 phosphorylates BAD at Ser112 in human colon cancer cells, inactivating BAD to prevent apoptosis; PIM3 knockdown specifically abrogated Ser112 phosphorylation and promoted apoptosis.","method":"shRNA knockdown, Western blot, co-localization by immunohistochemistry","journal":"Cancer Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — independently replicated in colon cancer confirming the pancreatic cancer findings, reciprocal IHC co-localization","pmids":["17270021"],"is_preprint":false},{"year":2005,"finding":"PIM3 is aberrantly expressed in human hepatocellular carcinoma cell lines but not normal liver; RNA interference-mediated ablation of PIM3 attenuated cell proliferation and enhanced apoptosis in hepatoma cell lines.","method":"RNA interference, cell proliferation assay, apoptosis assay; fluorescent differential display to identify gene","journal":"International Journal of Cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean KD with defined cellular phenotype in a single lab, two orthogonal readouts (proliferation + apoptosis)","pmids":["15540201"],"is_preprint":false},{"year":2003,"finding":"PIM3 is a direct transcriptional target of EWS/ETS oncoproteins; forced expression of PIM3 promotes anchorage-independent growth, and co-expression of a kinase-deficient PIM3 mutant attenuated EWS/FLI1-mediated tumorigenesis in immunodeficient mice.","method":"Microarray expression analysis, forced expression assay, kinase-dead mutant co-expression, in vivo tumorigenesis assay","journal":"Molecular and Cellular Biology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — kinase-dead mutant rescue + in vivo functional validation in one study","pmids":["12748291"],"is_preprint":false},{"year":2008,"finding":"The transcription factor Ets-1 binds the PIM3 promoter (between -249 and -183 bp) and drives constitutive PIM3 expression in human pancreatic cancer cells; mutation of the Ets-1 binding site (-216 to -211 bp) reduced promoter activity, and dominant-negative Ets-1 or Ets-1 siRNA reduced PIM3 expression, pBAD(Ser112) levels, and induced apoptosis—effects reversed by PIM3 cDNA re-introduction.","method":"Luciferase reporter with deletion mutants, chromatin immunoprecipitation (ChIP), dominant-negative transfection, Ets-1 siRNA, rescue experiment with PIM3 cDNA","journal":"Cancer Science","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — ChIP + reporter assay + mutagenesis + functional rescue in one study","pmids":["19154409"],"is_preprint":false},{"year":2009,"finding":"PIM3 (along with PIM1) phosphorylates the KSHV latency-associated nuclear antigen LANA on serine residues 205 and 206, counteracting LANA-mediated repression of lytic gene transcription and thereby promoting KSHV reactivation from latency.","method":"Overexpression of Pim kinases, identification of phosphorylation sites on LANA, KSHV reactivation assays in naturally infected cells","journal":"PLoS Pathogens","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — specific phosphorylation sites identified with functional validation, single lab","pmids":["19266083"],"is_preprint":false},{"year":2007,"finding":"PIM3 expression in mouse embryonic stem cells is upregulated by LIF/gp130/STAT3 signaling; overexpression of PIM3 enhanced ES cell self-renewal and resistance to LIF withdrawal, while knockdown increased spontaneous differentiation and apoptosis.","method":"Granulocyte colony-stimulating factor:gp130 chimeric receptor + hormone-dependent STAT3-ER system, clonal self-renewal assay, shRNA knockdown","journal":"Stem Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean gain- and loss-of-function with defined phenotypic readout, single lab","pmids":["17717068"],"is_preprint":false},{"year":2010,"finding":"PIM3 liver-specific transgenic mice do not develop spontaneous HCC but show accelerated hepatocyte cell cycle progression; upon diethylnitrosamine (DEN) treatment, these mice develop HCC with higher incidence (80% vs 40%) and heavier tumor burden, demonstrating PIM3 acts as a tumor promoter rather than initiator.","method":"Liver-specific transgenic mouse model, DEN-induced hepatocarcinogenesis, histological analysis, immunohistochemistry for proliferating cells and CD31+ vascular areas","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo transgenic model with clear mechanistic distinction (promoter vs. initiator), multiple readouts","pmids":["20101231"],"is_preprint":false},{"year":2009,"finding":"PIM3 is expressed at high levels in endothelial cells where it localizes to lamellipodia and co-localizes with focal adhesion kinase (FAK); treatment with the actin polymerization inhibitor cytochalasin D dispersed PIM3 from lamellipodia; siRNA-mediated PIM3 knockdown impaired EC spreading, migration, proliferation, and tube-like structure formation in Matrigel assay.","method":"Immunofluorescence localization, co-localization with FAK, cytochalasin D treatment, siRNA knockdown, Matrigel tube formation assay","journal":"Journal of Cellular Physiology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — localization experiment tied to functional consequence, multiple cellular readouts","pmids":["19229879"],"is_preprint":false},{"year":2013,"finding":"Translationally controlled tumor protein (TCTP) interacts with PIM3 through PIM3's C-terminal region and TCTP's N-terminal region; TCTP overexpression increases PIM3 protein levels dose-dependently, while TCTP knockdown reduces PIM3 protein (but not mRNA) via the ubiquitin-proteasome degradation system, establishing TCTP as a regulator of PIM3 protein stability.","method":"Yeast two-hybrid screen, co-immunoprecipitation, domain mapping, RNAi-mediated knockdown, proteasome inhibitor experiments, in vitro and in vivo tumor growth assays","journal":"Molecular Cancer Research","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — yeast two-hybrid + Co-IP + domain mapping + proteasomal mechanism + in vivo validation in one study","pmids":["24165482"],"is_preprint":false},{"year":2011,"finding":"PIM3 is a direct transcriptional target of c-Myc, which binds to conserved E-boxes in the PIM3 gene; lymphomas in Myc-transgenic mice and Burkitt lymphoma cell lines exhibit elevated PIM3 levels; pan-PIM kinase inhibition in Myc-induced lymphoma causes caspase-independent cell death.","method":"Chromatin immunoprecipitation (ChIP) for c-Myc binding to PIM3 E-boxes, pharmacological Pim kinase inhibitor, cell death assay","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirms direct target binding, functional pharmacological inhibition, single lab","pmids":["21646687"],"is_preprint":false},{"year":2010,"finding":"PIM3 negatively regulates glucose-stimulated insulin secretion in pancreatic β-cells; Pim3-/- mice show enhanced second-phase insulin secretion, increased glucose tolerance, and increased insulin sensitivity; PIM3 physically interacts with SOCS6, whose levels are reduced in Pim3-/- islets; overexpression of SOCS6 inhibits glucose-induced ERK1/2 activation, suggesting PIM3 suppresses insulin secretion by inhibiting ERK1/2 through SOCS6.","method":"Pim3 knockout mouse, glucose-stimulated insulin secretion assay in MIN6 cells and isolated islets, in vivo glucose tolerance test, ERK1/2 phosphorylation assay, co-immunoprecipitation for SOCS6, SOCS6 overexpression","journal":"Islets","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — knockout mouse + in vitro + in vivo + Co-IP + epistasis (SOCS6 OE rescuing ERK activity) in one study","pmids":["21099329"],"is_preprint":false},{"year":2014,"finding":"PIM3 kinase activity promotes pancreatic cancer vasculogenesis and tumor growth; wild-type PIM3 overexpression increased Bad(Ser112) phosphorylation and proliferation, while kinase-dead PIM3 (K69M mutant) reduced these effects; PIM3 upregulated pSTAT3(Tyr705), pSurvivin(Thr34), and angiogenic factors including VEGF, HGF, EGF, and FGF-2 in a kinase-dependent manner.","method":"Stable overexpression of wild-type vs. kinase-dead K69M-PIM3 mutant, shRNA knockdown, xenograft mouse model, Western blot, histological analysis of CD31+ vascular areas","journal":"Oncology Reports","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — kinase-dead mutant comparison establishes kinase-dependence with multiple downstream readouts in vitro and in vivo","pmids":["24789328"],"is_preprint":false},{"year":2015,"finding":"miR-33a directly targets the 3'-UTR of PIM3 mRNA to suppress its expression in pancreatic cancer; PIM3 suppression by miR-33a leads to downregulation of the AKT/GSK-3β/β-catenin pathway, inhibiting tumor growth and increasing gemcitabine chemosensitivity.","method":"Dual luciferase reporter assay for miR-33a targeting PIM3 3'-UTR, Western blot for downstream signaling, in vitro and in vivo proliferation/chemosensitivity assays","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — luciferase reporter confirms direct targeting, pathway effects measured, single lab","pmids":["25971209"],"is_preprint":false},{"year":2017,"finding":"mTORC1 suppresses PIM3 expression via SREBP transcription factors and miR-33 (an intronic microRNA encoded within the SREBP loci); rapamycin inhibition of mTORC1 induces PIM3 transcript and protein levels; this pathway operates in cells with TSC loss-of-function and in mouse liver upon feeding.","method":"Rapamycin treatment, TSC knockout cells, SREBP manipulation, miR-33 expression analysis, in vivo mouse liver feeding experiments","journal":"Scientific Reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple genetic contexts tested, in vivo validation, single lab","pmids":["29167471","29170467"],"is_preprint":false},{"year":2018,"finding":"PIM3 promotes melanoma cell migration and invasion by promoting STAT3 phosphorylation, which induces expression of EMT-related transcription factors Slug, Snail, and ZEB1; PIM3 knockdown inhibited B16F10 cell migration in vitro and reduced pulmonary metastasis in a tumor-bearing mouse model.","method":"shRNA knockdown, in vitro migration/invasion assay, in vivo metastasis mouse model, Western blot for STAT3 phosphorylation and EMT markers","journal":"Cancer Biology & Therapy","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — KD with in vivo validation, pathway placement via STAT3/EMT markers, single lab","pmids":["29370558"],"is_preprint":false},{"year":2016,"finding":"PIM3 contributes to radioresistance in pancreatic cancer cells by attenuating G2/M phase cell cycle arrest and DNA damage response; PIM3 silencing elevated phosphorylation of histone H2AX (γH2AX, a DNA double-strand break marker) and decreased ATM kinase activation, enhancing radiosensitivity in vitro and in vivo.","method":"Stable PIM3 overexpression and shRNA knockdown, γH2AX and ATM phosphorylation by Western blot, cell cycle analysis, xenograft in vivo radiosensitivity assay","journal":"Biochemical and Biophysical Research Communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with defined molecular readouts and in vivo validation, single lab","pmids":["27016481"],"is_preprint":false},{"year":2009,"finding":"PIM3 expression in cardiomyocytes is upregulated by anoxic preconditioning via a p38 MAPK signaling pathway; transfection of PIM3 into rat cardiomyocytes attenuated anoxia/reoxygenation injury; inhibition of p38 MAPK by SB203580 abolished both PIM3 upregulation and the cardioprotective effect.","method":"PIM3 expression vector transfection into rat cardiomyocytes, p38 MAPK inhibitor (SB203580), anoxia/reoxygenation model, cell viability and apoptosis assays","journal":"International Journal of Biochemistry & Cell Biology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — pharmacological epistasis + gain-of-function with functional readout, single lab","pmids":["19505587"],"is_preprint":false},{"year":2020,"finding":"PIM3 overexpression promotes liver cancer cell migration by activating RhoA GTPase through phosphorylation of multiple Rho GTPase modulators, leading to cytoskeletal rearrangements; quantitative phosphoproteomics revealed PIM3-induced phosphorylation changes across signal transduction, cell cycle, and apoptosis networks.","method":"Quantitative proteomics and phosphoproteomics in PIM3-overexpressing liver cancer cells, RhoA activity assay, cytoskeletal analysis","journal":"Journal of Proteome Research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phosphoproteomics + functional validation of RhoA activation + cytoskeletal readout, single lab","pmids":["31994402"],"is_preprint":false},{"year":2020,"finding":"PIM3 overexpression promotes AML cell migration via CXCR4; PIM3-overexpressing AML cells exhibited increased CXCR4 phosphorylation at Ser339, and phosphorylated CXCR4 physically interacted with PIM3 by co-immunoprecipitation; PIM3 also phosphorylated BAD at Ser112 to protect against apoptosis.","method":"Co-immunoprecipitation of PIM3 and pCXCR4(Ser339), cell migration assay, Western blot for pBAD(Ser112), flow cytometry","journal":"OncoTargets and Therapy","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — Co-IP confirms PIM3/pCXCR4 interaction, functional migration assay, single lab","pmids":["32764981"],"is_preprint":false},{"year":2022,"finding":"PIM3 suppresses the totipotent 2-cell-like state in embryonic stem cells via an AMPK-HDAC4/5 axis; loss of PIM3 increases AMPK phosphorylation, causing HDAC4/5 nuclear export, which reduces H3K9me1/2 and increases H3K9ac on MuERVL retroviral elements, thereby activating 2-cell genes.","method":"PIM3 knockout ESCs, AMPK phosphorylation assays, HDAC4/5 nuclear/cytoplasmic fractionation, chromatin modification (H3K9ac, H3K9me1/2) analysis at MuERVL loci, pharmacological PIM3 inhibition","journal":"Stem Cell Reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO + epistasis through AMPK/HDAC axis + chromatin readout, single lab","pmids":["36150380"],"is_preprint":false},{"year":2017,"finding":"In adult T-cell leukemia, viral Tax protein induces PIM3 expression through NF-κB signaling; PIM3 knockdown inhibited growth of HTLV-1-infected T cells; PIM1/3 kinase inhibitor NJC97-NH induced G2/M arrest with downregulation of cyclin A and cyclin B1, and apoptosis with downregulation of XIAP and Mcl-1 via inhibition of NF-κB (decreased IκBα and RelA phosphorylation).","method":"siRNA knockdown of PIM3 and RelA, pharmacological Pim inhibitor, EMSA for NF-κB DNA binding, Western blot, cell cycle and apoptosis analysis","journal":"European Journal of Haematology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — epistasis (Tax→NF-κB→PIM3) with multiple readouts, EMSA confirms NF-κB binding, single lab","pmids":["28833639"],"is_preprint":false},{"year":2017,"finding":"PIM3 maintains stemness of pancreatic cancer cells by activating the STAT3 signaling pathway; PIM3 silencing decreased proportions of CD24+ESA+ cancer stem-like cells and reduced stemness-associated transcription factors including STAT3 phosphorylation; restoration of STAT3 activity rescued the stem cell-like phenotype in PIM3-silenced cells.","method":"PIM3 siRNA knockdown, STAT3 phosphorylation/transcriptional activity assay, CD24+ESA+ cell population flow cytometry, STAT3 rescue experiment","journal":"Journal of Cancer","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — KD + rescue epistasis through STAT3, single lab","pmids":["28775772"],"is_preprint":false},{"year":2019,"finding":"Aldosterone stimulates PIM3 expression in the distal nephron in vitro (mCCDcl1 cells), ex vivo (mouse kidney slices), and in vivo; Pim3-/- mice display upregulated RAAS (elevated aldosterone and plasma renin activity) but no overt salt-losing phenotype, potentially compensated by upregulation of PIM1 and PIM2 in the kidney.","method":"Germline Pim3 knockout mouse, aldosterone treatment in multiple systems, electrolyte/blood pressure measurements, expression analysis of PIM family members and Na+ transporters","journal":"Physiological Reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockout mouse model with in vitro/ex vivo/in vivo corroboration, single lab","pmids":["31397090"],"is_preprint":false},{"year":2022,"finding":"PIM3 kinase promotes hepatoblastoma metastasis by upregulating phosphorylation and cell surface expression of CXCR4; PIM3 knockout by CRISPR/Cas9 impaired lung metastasis formation in vivo; CXCR4 blockade with AMD3100 decreased the metastatic phenotype of PIM3-overexpressing cells.","method":"CRISPR/Cas9 PIM3 knockout, stable PIM3 overexpression, tail vein injection metastasis model, AMD3100 CXCR4 blockade, CXCR4 surface expression analysis","journal":"Clinical & Experimental Metastasis","confidence":"High","confidence_rationale":"Tier 2 / Strong — CRISPR KO + OE + pharmacological blockade + in vivo metastasis model + mechanistic rescue, single lab with multiple orthogonal methods","pmids":["36315303"],"is_preprint":false},{"year":2021,"finding":"CRISPR/Cas9-mediated PIM3 knockout in hepatoblastoma cells decreased proliferation, viability, motility, tumor growth in xenograft model, and cancer cell stemness (tumorsphere formation, CD133 expression, stemness marker mRNAs); reintroduction of PIM3 rescued the malignant phenotype.","method":"CRISPR/Cas9 dual gRNA knockout, xenograft murine model, RNA sequencing, tumorsphere assay, CD133 flow cytometry, PIM3 rescue experiment","journal":"Cancer Gene Therapy","confidence":"High","confidence_rationale":"Tier 2 / Strong — CRISPR KO with genetic rescue + in vivo + transcriptomic analysis, multiple orthogonal readouts","pmids":["33864024"],"is_preprint":false},{"year":2025,"finding":"PIM3-mediated phosphorylation of myeloid leukemia factor 2 (MLF2) at Ser65 enhances MLF2 stability by promoting its interaction with the deubiquitinase USP21, thereby protecting MLF2 from STUB1-mediated ubiquitination and proteasomal degradation at Lys119; MLF2 promotes osteosarcoma metastasis by disrupting the BiP-IRE1α interaction, activating the IRE1α/XBP1-S-MMP9 axis.","method":"In vivo CRISPR activation screen combined with STUB1 interactome, phosphorylation site mapping, ubiquitination assays, Co-IP for USP21/MLF2/PIM3 interactions, xenograft metastasis model","journal":"Journal of Clinical Investigation","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — phosphorylation site identification + ubiquitination mechanism + protein-protein interaction mapping + in vivo validation in one rigorous study","pmids":["41090348"],"is_preprint":false},{"year":2024,"finding":"PIM3 inhibition increases vascular leakage and metastatic colonization in the lung; endothelial PIM3 (activated by JAK-STAT) protects the vascular barrier by maintaining junctional cadherin-5 and catenins α, β, and δ at endothelial cell junctions; PIM inhibition impairs the EC barrier.","method":"scRNA-seq of lung ECs in metastasis models, pharmacological PIM inhibition, vascular permeability assay, junctional protein expression analysis, spontaneous metastasis mouse models","journal":"Nature Communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — scRNA-seq identification + functional inhibition in vivo + defined molecular mechanism (junctional proteins), replicated in multiple metastasis models","pmids":["39627185"],"is_preprint":false},{"year":2025,"finding":"PIM3 physically interacts with and activates the Akt signaling pathway in nucleus pulposus cells to regulate downstream mTOR and FoxO1, modulating cell viability and senescence in a kinase-activity-dependent manner; AAV-mediated PIM3 overexpression in an IDD rat model improved ECM integrity and reduced senescence.","method":"Co-immunoprecipitation of PIM3 and Akt, knockdown and overexpression including kinase-dead mutant, Akt/mTOR/FoxO1 phosphorylation assays, AAV in vivo model","journal":"Translational Research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP + kinase-dead comparison + in vivo validation, single lab","pmids":["41478528"],"is_preprint":false},{"year":2023,"finding":"PIM3 phosphorylates MAPK1 (ERK2) at T185 and Y187 in esophageal squamous cell carcinoma cells, promoting cell proliferation and tumor development; corynoline directly binds PIM3 and inhibits its kinase activity; PIM3 deletion induced apoptosis with upregulated cleaved caspase-9 and reduced BAD phosphorylation at S112.","method":"Pull-down assay, cellular thermal shift assay (CETSA), kinase assay, Western blot for pMAPK1(T185/Y187) and pBAD(S112), patient-derived xenograft model","journal":"Phytomedicine","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — kinase assay + CETSA + PDX model identifies new substrate MAPK1, single lab","pmids":["38128397"],"is_preprint":false},{"year":2025,"finding":"PIM3 is upregulated by the transcription factor YY1, which translocates from the cytoplasm to the nucleus under hyperglycemia and binds the PIM3 promoter, enhancing PIM3 transcriptional activity; PIM3 or YY1 knockdown reduced cardiac hypertrophy markers and attenuated diabetic cardiac dysfunction in mice.","method":"Chromatin immunoprecipitation (ChIP) and luciferase reporter assay for YY1-PIM3 promoter interaction, siRNA and lentivirus-mediated knockdown, streptozotocin diabetic mouse model, echocardiography","journal":"Iranian Journal of Basic Medical Sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP + reporter assay + in vivo mouse model, single lab","pmids":["39850120"],"is_preprint":false},{"year":2025,"finding":"The compound CSH-4044 (isolated from fermented wheat germ extract) is an ATP-competitive inhibitor of PIM kinases including PIM3; it suppresses PIM3-driven BAD phosphorylation in pancreatic cancer cells; co-crystal structure of CSH-4044 with PIM1 revealed critical hydrophobic and hydrogen-bonding interactions at the ATP binding site.","method":"X-ray co-crystallography of PIM1-CSH-4044, kinase profiling, BAD phosphorylation assay in pancreatic cancer cells","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — crystal structure + kinase assay + cellular readout in single preprint, not yet peer-reviewed","pmids":["bio_10.1101_2025.10.22.683941"],"is_preprint":true},{"year":2019,"finding":"Knockdown of PIM3 inhibits ferroptosis in myocardial I/R injury, alleviating myocardial damage; PIM3 expression is increased by myocardial I/R or OGD/R, and PIM3 silencing reduced ROS, MDA, and iron content while increasing SOD, GPX4, and FTH1.","method":"In vivo rat myocardial I/R model, H9c2 OGD/R cell model, siRNA knockdown, Western blot for ferroptosis markers (TfR1, FTH1, GPX4), ROS/MDA/SOD assays","journal":"Genes & Genomics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — KD with phenotypic readout but no direct mechanistic pathway placement for PIM3 in ferroptosis, single lab","pmids":["38148455"],"is_preprint":false},{"year":2025,"finding":"ETS1 transcription factor promotes PIM3 expression under OGD/R conditions (simulating myocardial ischemia-reperfusion injury) by binding the PIM3 promoter; ETS1 knockdown suppressed ferroptosis and myocardial injury through reducing PIM3 expression; the ETS1→PIM3 axis exacerbates ferroptosis in cardiomyocytes.","method":"OGD/R H9C2 cell model, mouse MIRI model, ETS1 knockdown, Western blot for ETS1/PIM3/ferroptosis markers (GPX4, SLC7A11, FTH1), immunofluorescence","journal":"Experimental Cell Research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — epistasis implied but ChIP/promoter binding for ETS1-PIM3 not explicitly described in abstract, single lab","pmids":["40189183"],"is_preprint":false},{"year":2019,"finding":"Cholesterol promotes CRC cell proliferation partly through the miR-33a/PIM3 axis; PIM3 was identified as a direct target of miR-33a by dual luciferase reporter assay; PIM3 modulates CRC cell proliferation and apoptosis by phosphorylating p27, p21, and BAD.","method":"Dual luciferase reporter assay, Western blot for pBad/pp27/pp21, CCK-8 and flow cytometry with cholesterol treatment and miR-33a manipulation","journal":"Biochemical and Biophysical Research Communications","confidence":"Low","confidence_rationale":"Tier 3 / Weak — direct targeting confirmed by luciferase, but phosphorylation of p27 and p21 by PIM3 not directly demonstrated by kinase assay, single lab","pmids":["30827510"],"is_preprint":false}],"current_model":"PIM3 is a constitutively active serine/threonine kinase whose principal established substrates include BAD (phosphorylated at Ser112 to suppress apoptosis), LANA (phosphorylated at Ser205/206 to enable KSHV reactivation), MLF2 (phosphorylated at Ser65 to stabilize it via USP21 recruitment), CXCR4 (phosphorylated at Ser339 to promote cell migration), and MAPK1/ERK2 (phosphorylated at T185/Y187 to drive proliferation); PIM3 expression is transcriptionally regulated by Ets-1, c-Myc, STAT3, YY1, and EWS/ETS fusion proteins, post-translationally stabilized by TCTP (which prevents ubiquitin-proteasomal degradation), and suppressed post-transcriptionally by mTORC1 via SREBP-encoded miR-33; PIM3 localizes to lamellipodia in endothelial cells (dependent on actin polymerization) and at endothelial junctions where it maintains cadherin-5 and catenin expression to protect vascular barrier integrity; in β-cells PIM3 negatively regulates glucose-stimulated insulin secretion by suppressing ERK1/2 activation through SOCS6; and in embryonic stem cells PIM3 represses totipotency by activating AMPK-HDAC4/5-mediated histone methylation at MuERVL loci."},"narrative":{"mechanistic_narrative":"PIM3 is a constitutively active serine/threonine kinase that functions broadly as a pro-survival, pro-proliferative, and pro-migratory effector across cancer, vascular, endocrine, and stem-cell contexts [PMID:16818649, PMID:24789328]. Its best-characterized substrate is the pro-apoptotic protein BAD, which PIM3 phosphorylates specifically at Ser112 (not Ser136) to inactivate it and suppress apoptosis—an activity replicated across pancreatic, colon, hepatoma, and leukemic cells [PMID:16818649, PMID:17270021, PMID:32764981]. Beyond BAD, PIM3 phosphorylates a defined substrate set that explains its diverse phenotypes: MAPK1/ERK2 at T185/Y187 to drive proliferation [PMID:38128397], CXCR4 at Ser339 to promote migration and metastatic colonization [PMID:32764981, PMID:36315303], the KSHV antigen LANA at Ser205/206 to enable viral reactivation [PMID:19266083], and MLF2 at Ser65 to stabilize it via USP21-mediated protection from STUB1 ubiquitination [PMID:41090348]. Its kinase activity is required for these outputs, as kinase-dead mutants (e.g., K69M) abolish BAD phosphorylation, proliferation, and tumor-promoting vasculogenesis [PMID:12748291, PMID:24789328]. PIM3 expression is transcriptionally driven by multiple oncogenic inputs—EWS/ETS fusions [PMID:12748291], Ets-1 [PMID:19154409], c-Myc [PMID:21646687], Tax/NF-κB [PMID:28833639], and YY1 [PMID:39850120]—and is post-translationally stabilized by TCTP, which binds PIM3's C-terminus to block its ubiquitin-proteasomal degradation [PMID:24165482]; conversely, mTORC1 represses PIM3 via SREBP-encoded miR-33 [PMID:29167471, PMID:29170467]. In normal physiology, PIM3 negatively regulates glucose-stimulated insulin secretion in β-cells by suppressing ERK1/2 through SOCS6 [PMID:21099329], protects the endothelial vascular barrier by maintaining junctional cadherin-5 and catenins [PMID:39627185], and represses the totipotent 2-cell-like state in embryonic stem cells via an AMPK–HDAC4/5 axis that silences MuERVL elements [PMID:36150380]. As an oncogene PIM3 acts as a tumor promoter rather than initiator, accelerating hepatocyte cell cycle progression without inducing spontaneous tumors [PMID:20101231].","teleology":[{"year":2003,"claim":"Established PIM3 as an oncogenic effector downstream of a fusion oncoprotein, answering whether its kinase activity is functionally required for transformation.","evidence":"Microarray, forced expression, kinase-dead co-expression, and in vivo tumorigenesis in immunodeficient mice for EWS/ETS-driven Ewing sarcoma","pmids":["12748291"],"confidence":"High","gaps":["Did not identify direct phosphorylation substrates","Mechanism of anchorage-independent growth not resolved at the molecular level"]},{"year":2006,"claim":"Identified BAD Ser112 as a direct PIM3 phosphorylation target, defining the molecular basis of its anti-apoptotic activity.","evidence":"shRNA knockdown and phospho-specific Western blot in pancreatic cancer cells; replicated in colon cancer (2007)","pmids":["16818649","17270021"],"confidence":"High","gaps":["Site specificity (Ser112 vs Ser136) shown by KD but not by in vitro kinase assay in original work","Other pro-survival substrates not yet mapped"]},{"year":2009,"claim":"Extended PIM3 substrate range beyond cancer to a viral target, showing it phosphorylates KSHV LANA at Ser205/206 to drive lytic reactivation.","evidence":"Pim kinase overexpression, phosphosite identification, and reactivation assays in naturally infected cells","pmids":["19266083"],"confidence":"Medium","gaps":["Redundancy with PIM1 not fully separated","Physiological PIM3 levels during natural reactivation not established"]},{"year":2010,"claim":"Distinguished PIM3 as a tumor promoter rather than an initiator, clarifying its causal role in hepatocarcinogenesis.","evidence":"Liver-specific transgenic mice with DEN-induced HCC and proliferation/vascular readouts","pmids":["20101231"],"confidence":"High","gaps":["Direct substrate driving accelerated cell cycle in vivo not identified","No spontaneous tumor model"]},{"year":2009,"claim":"Defined a non-cancer cellular role: PIM3 localizes to lamellipodia in an actin-dependent manner and is required for endothelial migration and tube formation.","evidence":"Immunofluorescence, cytochalasin D treatment, FAK co-localization, and siRNA functional assays in endothelial cells","pmids":["19229879"],"confidence":"Medium","gaps":["No cytoskeletal substrate identified at this stage","Mechanism linking localization to migration unresolved"]},{"year":2013,"claim":"Revealed how PIM3 protein levels are controlled, identifying TCTP as a stabilizer that blocks proteasomal degradation.","evidence":"Yeast two-hybrid, Co-IP, domain mapping, proteasome inhibitor experiments, and in vivo tumor growth","pmids":["24165482"],"confidence":"High","gaps":["E3 ligase mediating PIM3 ubiquitination not identified","Mechanism by which TCTP shields PIM3 unknown"]},{"year":2011,"claim":"Placed PIM3 within the c-Myc transcriptional program, identifying it as a direct Myc target and a vulnerability in Myc-driven lymphoma.","evidence":"ChIP for c-Myc at PIM3 E-boxes, pan-PIM inhibition, and cell death assays in Myc-transgenic/Burkitt models","pmids":["21646687"],"confidence":"Medium","gaps":["Caspase-independent death mechanism not defined","PIM3-specific (vs pan-PIM) contribution not isolated"]},{"year":2011,"claim":"Uncovered a normal endocrine function: PIM3 restrains glucose-stimulated insulin secretion via SOCS6-mediated ERK1/2 suppression.","evidence":"Pim3 knockout mice, GSIS assays, glucose tolerance tests, Co-IP for SOCS6, and SOCS6 overexpression epistasis","pmids":["21099329"],"confidence":"High","gaps":["Direct phosphorylation target linking PIM3 to SOCS6 not shown","Compensation by other PIM family members not excluded"]},{"year":2014,"claim":"Established kinase-dependence of PIM3's pro-angiogenic and proliferative output using a kinase-dead K69M mutant.","evidence":"Wild-type vs K69M overexpression, shRNA, xenograft, and angiogenic factor profiling in pancreatic cancer","pmids":["24789328"],"confidence":"High","gaps":["Whether STAT3/Survivin/VEGF effects are direct substrates or downstream consequences unresolved"]},{"year":2015,"claim":"Identified post-transcriptional repression of PIM3 by miR-33a and linked PIM3 to AKT/GSK-3β/β-catenin signaling and chemoresistance.","evidence":"Dual luciferase reporter, pathway Western blots, and in vivo chemosensitivity assays in pancreatic cancer","pmids":["25971209"],"confidence":"Medium","gaps":["Direct PIM3 substrate in the AKT/GSK-3β axis not identified","Single regulatory miRNA tested"]},{"year":2017,"claim":"Connected PIM3 regulation to nutrient/growth signaling, showing mTORC1 suppresses PIM3 via SREBP and miR-33.","evidence":"Rapamycin treatment, TSC knockout cells, SREBP manipulation, and in vivo mouse liver feeding","pmids":["29167471","29170467"],"confidence":"Medium","gaps":["Functional consequence of PIM3 induction under mTORC1 inhibition not fully characterized","Single lab"]},{"year":2017,"claim":"Demonstrated PIM3 supports cancer stemness through STAT3 activation in pancreatic cancer.","evidence":"siRNA knockdown, STAT3 activity assays, CD24+ESA+ flow cytometry, and STAT3 rescue","pmids":["28775772"],"confidence":"Medium","gaps":["Whether STAT3 phosphorylation is direct or indirect not established"]},{"year":2018,"claim":"Extended PIM3's migratory role to melanoma metastasis via STAT3-driven EMT.","evidence":"shRNA, migration/invasion assays, in vivo metastasis model, and EMT marker Western blots","pmids":["29370558"],"confidence":"Medium","gaps":["Direct STAT3 phosphorylation by PIM3 not demonstrated by kinase assay"]},{"year":2020,"claim":"Used phosphoproteomics to broaden the PIM3 signaling map and identify RhoA activation driving cytoskeletal rearrangement and migration.","evidence":"Quantitative phosphoproteomics, RhoA activity assay, and cytoskeletal analysis in liver cancer cells","pmids":["31994402"],"confidence":"Medium","gaps":["Direct Rho-modulator substrates inferred from phosphoproteomics not individually validated"]},{"year":2020,"claim":"Identified CXCR4 Ser339 as a PIM3 phosphorylation target promoting AML migration.","evidence":"Co-IP of PIM3 with pCXCR4(Ser339), migration assay, and pBAD(Ser112) Western blot","pmids":["32764981"],"confidence":"Medium","gaps":["Direct in vitro kinase assay on CXCR4 not shown","Single cancer type"]},{"year":2022,"claim":"Validated the PIM3-CXCR4 axis as a driver of metastasis using genetic and pharmacological loss-of-function.","evidence":"CRISPR/Cas9 knockout, overexpression, AMD3100 CXCR4 blockade, and tail-vein metastasis in hepatoblastoma","pmids":["36315303"],"confidence":"High","gaps":["Whether surface CXCR4 increase is solely phosphorylation-driven not isolated"]},{"year":2022,"claim":"Revealed a developmental role: PIM3 represses the totipotent 2-cell-like state via an AMPK-HDAC4/5-MuERVL chromatin axis.","evidence":"PIM3 knockout ESCs, AMPK phosphorylation, HDAC4/5 fractionation, and chromatin modification analysis at MuERVL loci","pmids":["36150380"],"confidence":"Medium","gaps":["Direct PIM3 substrate upstream of AMPK not identified","Single lab"]},{"year":2023,"claim":"Identified MAPK1/ERK2 (T185/Y187) as a direct PIM3 substrate driving proliferation, and a small-molecule inhibitor (corynoline).","evidence":"Pull-down, CETSA, in vitro kinase assay, and patient-derived xenograft in esophageal carcinoma","pmids":["38128397"],"confidence":"Medium","gaps":["Dual-residue (T/Y) phosphorylation mechanism by a Ser/Thr kinase not mechanistically explained","Single lab"]},{"year":2024,"claim":"Established a protective vascular function distinct from its oncogenic roles: endothelial PIM3 maintains junctional integrity to limit metastatic colonization.","evidence":"scRNA-seq of lung endothelial cells, pharmacological PIM inhibition, permeability assays, and multiple metastasis models","pmids":["39627185"],"confidence":"High","gaps":["Direct junctional-protein substrate not identified","PIM3-specific vs pan-PIM contribution not separated pharmacologically"]},{"year":2025,"claim":"Defined a stabilization mechanism whereby PIM3 phosphorylates MLF2 at Ser65 to recruit USP21 and protect it from STUB1-mediated degradation, driving osteosarcoma metastasis.","evidence":"In vivo CRISPR activation screen, phosphosite mapping, ubiquitination assays, Co-IP, and xenograft metastasis","pmids":["41090348"],"confidence":"High","gaps":["Generality of phospho-stabilization mechanism to other substrates unknown"]},{"year":null,"claim":"How PIM3 achieves overlapping but context-specific substrate selection, and whether its protective (endothelial barrier, β-cell) versus oncogenic functions reflect distinct substrate pools, complexes, or localizations, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural basis for substrate selectivity established for PIM3 itself","Functional redundancy with PIM1/PIM2 incompletely mapped","Most disease-context substrates inferred without in vitro kinase validation"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,5,19,26,29]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,12,29]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[31]}],"localization":[{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[8,18]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[8,27]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,1]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[11,22,28,29]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,7,24,26]}],"complexes":[],"partners":["BAD","TCTP","SOCS6","CXCR4","MLF2","USP21","AKT","MAPK1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q86V86","full_name":"Serine/threonine-protein kinase pim-3","aliases":[],"length_aa":326,"mass_kda":35.9,"function":"Proto-oncogene with serine/threonine kinase activity that can prevent apoptosis, promote cell survival and protein translation. May contribute to tumorigenesis through: the delivery of survival signaling through phosphorylation of BAD which induces release of the anti-apoptotic protein Bcl-X(L), the regulation of cell cycle progression, protein synthesis and by regulation of MYC transcriptional activity. Additionally to this role on tumorigenesis, can also negatively regulate insulin secretion by inhibiting the activation of MAPK1/3 (ERK1/2), through SOCS6. Involved also in the control of energy metabolism and regulation of AMPK activity in modulating MYC and PPARGC1A protein levels and cell growth","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q86V86/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PIM3","classification":"Not Classified","n_dependent_lines":27,"n_total_lines":1208,"dependency_fraction":0.022350993377483443},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PIM3","total_profiled":1310},"omim":[{"mim_id":"610580","title":"ONCOGENE PIM3; PIM3","url":"https://www.omim.org/entry/610580"},{"mim_id":"606232","title":"PHELAN-MCDERMID SYNDROME; PHMDS","url":"https://www.omim.org/entry/606232"},{"mim_id":"300295","title":"PIM2 PROTOONCOGENE, SERINE/THREONINE KINASE; PIM2","url":"https://www.omim.org/entry/300295"},{"mim_id":"164960","title":"ONCOGENE PIM 1; PIM1","url":"https://www.omim.org/entry/164960"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/PIM3"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q86V86","domains":[{"cath_id":"3.30.200.20","chopping":"38-125","consensus_level":"high","plddt":92.4706,"start":38,"end":125},{"cath_id":"1.10.510.10","chopping":"130-295","consensus_level":"high","plddt":97.413,"start":130,"end":295}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q86V86","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q86V86-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q86V86-F1-predicted_aligned_error_v6.png","plddt_mean":84.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PIM3","jax_strain_url":"https://www.jax.org/strain/search?query=PIM3"},"sequence":{"accession":"Q86V86","fasta_url":"https://rest.uniprot.org/uniprotkb/Q86V86.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q86V86/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q86V86"}},"corpus_meta":[{"pmid":"16818649","id":"PMC_16818649","title":"Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16818649","citation_count":157,"is_preprint":false},{"pmid":"17270021","id":"PMC_17270021","title":"Proto-oncogene, Pim-3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad-mediated apoptosis.","date":"2007","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/17270021","citation_count":110,"is_preprint":false},{"pmid":"15540201","id":"PMC_15540201","title":"Aberrant expression of serine/threonine kinase Pim-3 in hepatocellular carcinoma development and its role in the proliferation of human hepatoma cell lines.","date":"2005","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15540201","citation_count":87,"is_preprint":false},{"pmid":"22727640","id":"PMC_22727640","title":"Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases.","date":"2012","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/22727640","citation_count":83,"is_preprint":false},{"pmid":"21518143","id":"PMC_21518143","title":"Roles of Pim-3, a novel survival kinase, in tumorigenesis.","date":"2011","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/21518143","citation_count":75,"is_preprint":false},{"pmid":"12748291","id":"PMC_12748291","title":"PIM3 proto-oncogene kinase is a common transcriptional target of divergent EWS/ETS oncoproteins.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12748291","citation_count":68,"is_preprint":false},{"pmid":"17876606","id":"PMC_17876606","title":"Aberrant Pim-3 expression is involved in gastric adenoma-adenocarcinoma sequence and cancer progression.","date":"2007","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17876606","citation_count":66,"is_preprint":false},{"pmid":"25971209","id":"PMC_25971209","title":"MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25971209","citation_count":64,"is_preprint":false},{"pmid":"19266083","id":"PMC_19266083","title":"KSHV reactivation from latency requires Pim-1 and Pim-3 kinases to inactivate the latency-associated nuclear antigen LANA.","date":"2009","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/19266083","citation_count":60,"is_preprint":false},{"pmid":"17717068","id":"PMC_17717068","title":"Self-renewal of murine embryonic stem cells is supported by the serine/threonine kinases Pim-1 and Pim-3.","date":"2007","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/17717068","citation_count":58,"is_preprint":false},{"pmid":"20101231","id":"PMC_20101231","title":"Accelerated hepatocellular carcinoma development in mice expressing the Pim-3 transgene selectively in the liver.","date":"2010","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/20101231","citation_count":56,"is_preprint":false},{"pmid":"30827510","id":"PMC_30827510","title":"Cholesterol regulates cell proliferation and apoptosis of colorectal cancer by modulating miR-33a-PIM3 pathway.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30827510","citation_count":45,"is_preprint":false},{"pmid":"24165482","id":"PMC_24165482","title":"A novel regulatory mechanism of Pim-3 kinase stability and its involvement in pancreatic cancer progression.","date":"2013","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/24165482","citation_count":42,"is_preprint":false},{"pmid":"21646687","id":"PMC_21646687","title":"The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas.","date":"2011","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/21646687","citation_count":41,"is_preprint":false},{"pmid":"27638830","id":"PMC_27638830","title":"MiR-377 inhibits the proliferation of pancreatic cancer by targeting Pim-3.","date":"2016","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27638830","citation_count":40,"is_preprint":false},{"pmid":"21945284","id":"PMC_21945284","title":"Discovery of novel 3,5-disubstituted indole derivatives as potent inhibitors of Pim-1, Pim-2, and Pim-3 protein kinases.","date":"2011","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/21945284","citation_count":40,"is_preprint":false},{"pmid":"19154409","id":"PMC_19154409","title":"Essential contribution of Ets-1 to constitutive Pim-3 expression in human pancreatic cancer cells.","date":"2008","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/19154409","citation_count":36,"is_preprint":false},{"pmid":"25071334","id":"PMC_25071334","title":"Pathophysiological roles of Pim-3 kinase in pancreatic cancer development and progression.","date":"2014","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/25071334","citation_count":34,"is_preprint":false},{"pmid":"19229879","id":"PMC_19229879","title":"Pim-3 is expressed in endothelial cells and promotes vascular tube formation.","date":"2009","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19229879","citation_count":31,"is_preprint":false},{"pmid":"23760491","id":"PMC_23760491","title":"Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.","date":"2013","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/23760491","citation_count":30,"is_preprint":false},{"pmid":"19505587","id":"PMC_19505587","title":"Pim-3 protects against cardiomyocyte apoptosis in anoxia/reoxygenation injury via p38-mediated signal pathway.","date":"2009","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19505587","citation_count":27,"is_preprint":false},{"pmid":"29370558","id":"PMC_29370558","title":"Pim-3 enhances melanoma cell migration and invasion by promoting STAT3 phosphorylation.","date":"2018","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/29370558","citation_count":26,"is_preprint":false},{"pmid":"29069816","id":"PMC_29069816","title":"Ubenimex suppresses Pim-3 kinase expression by targeting CD13 to reverse MDR in HCC cells.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29069816","citation_count":26,"is_preprint":false},{"pmid":"27016481","id":"PMC_27016481","title":"Pim-3 contributes to radioresistance through regulation of the cell cycle and DNA damage repair in pancreatic cancer cells.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/27016481","citation_count":22,"is_preprint":false},{"pmid":"24789328","id":"PMC_24789328","title":"Pim-3 promotes human pancreatic cancer growth by regulating tumor vasculogenesis.","date":"2014","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/24789328","citation_count":21,"is_preprint":false},{"pmid":"26238203","id":"PMC_26238203","title":"MicroRNA‑506 participates in pancreatic cancer pathogenesis by targeting PIM3.","date":"2015","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/26238203","citation_count":20,"is_preprint":false},{"pmid":"31260686","id":"PMC_31260686","title":"Bufothionine exerts anti-cancer activities in gastric cancer through Pim3.","date":"2019","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31260686","citation_count":19,"is_preprint":false},{"pmid":"25921139","id":"PMC_25921139","title":"Aberrant expression of pim-3 promotes proliferation and migration of ovarian cancer cells.","date":"2015","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/25921139","citation_count":18,"is_preprint":false},{"pmid":"30654529","id":"PMC_30654529","title":"AZD1208, a Pan-Pim Kinase Inhibitor, Has Anti-Growth Effect on 93T449 Human Liposarcoma Cells via Control of the Expression and Phosphorylation of Pim-3, mTOR, 4EBP-1, S6, STAT-3 and AMPK.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30654529","citation_count":18,"is_preprint":false},{"pmid":"21099329","id":"PMC_21099329","title":"Pim3 negatively regulates glucose-stimulated insulin secretion.","date":"2010","source":"Islets","url":"https://pubmed.ncbi.nlm.nih.gov/21099329","citation_count":17,"is_preprint":false},{"pmid":"24488669","id":"PMC_24488669","title":"Differential expression of Pim-3, c-Myc, and p-p27 proteins in adenocarcinomas of the gastric cardia and distal stomach.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24488669","citation_count":17,"is_preprint":false},{"pmid":"20039932","id":"PMC_20039932","title":"Pim-3 protects against hepatic failure in D-galactosamine (D-GalN)-sensitized rats.","date":"2009","source":"European journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/20039932","citation_count":17,"is_preprint":false},{"pmid":"29167471","id":"PMC_29167471","title":"Pim-3 as a potential predictor of chemoradiotherapy resistance in locally advanced rectal cancer patients.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29167471","citation_count":16,"is_preprint":false},{"pmid":"33864024","id":"PMC_33864024","title":"CRISPR/Cas9-mediated knockout of PIM3 suppresses tumorigenesis and cancer cell stemness in human hepatoblastoma cells.","date":"2021","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33864024","citation_count":15,"is_preprint":false},{"pmid":"15820782","id":"PMC_15820782","title":"Association of the PIM3 allele of the alpha-1-antitrypsin gene with chronic obstructive pulmonary disease.","date":"2005","source":"Clinical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15820782","citation_count":15,"is_preprint":false},{"pmid":"23845873","id":"PMC_23845873","title":"Pim-3 promotes the growth of human pancreatic cancer in the orthotopic nude mouse model through vascular endothelium growth factor.","date":"2013","source":"The Journal of surgical research","url":"https://pubmed.ncbi.nlm.nih.gov/23845873","citation_count":15,"is_preprint":false},{"pmid":"38339286","id":"PMC_38339286","title":"PIM3 Kinase: A Promising Novel Target in Solid Cancers.","date":"2024","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/38339286","citation_count":13,"is_preprint":false},{"pmid":"31994402","id":"PMC_31994402","title":"Proto-Oncogene Serine/Threonine Kinase PIM3 Promotes Cell Migration via Modulating Rho GTPase Signaling.","date":"2020","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/31994402","citation_count":13,"is_preprint":false},{"pmid":"32764981","id":"PMC_32764981","title":"PIM3 Promotes the Proliferation and Migration of Acute Myeloid Leukemia Cells.","date":"2020","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32764981","citation_count":13,"is_preprint":false},{"pmid":"25817345","id":"PMC_25817345","title":"Knockdown of Pim-3 suppresses the tumorigenicity of glioblastoma by regulating cell cycle and apoptosis.","date":"2015","source":"Cellular and molecular biology (Noisy-le-Grand, France)","url":"https://pubmed.ncbi.nlm.nih.gov/25817345","citation_count":13,"is_preprint":false},{"pmid":"30898394","id":"PMC_30898394","title":"The presence of PIM3 increases hepatoblastoma tumorigenesis and tumor initiating cell phenotype and is associated with decreased patient survival.","date":"2019","source":"Journal of pediatric surgery","url":"https://pubmed.ncbi.nlm.nih.gov/30898394","citation_count":11,"is_preprint":false},{"pmid":"19624871","id":"PMC_19624871","title":"[Effect of ginsenoside Rg3 on Pim-3 and Bad proteins in human pancreatic cancer cell line PANC-1].","date":"2009","source":"Ai zheng = Aizheng = Chinese journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19624871","citation_count":11,"is_preprint":false},{"pmid":"30417983","id":"PMC_30417983","title":"PIM3 Functions as Oncogenic Factor and Promotes the Tumor Growth and Metastasis in Colorectal Cancer.","date":"2018","source":"Anatomical record (Hoboken, N.J. : 2007)","url":"https://pubmed.ncbi.nlm.nih.gov/30417983","citation_count":10,"is_preprint":false},{"pmid":"36150380","id":"PMC_36150380","title":"PIM3-AMPK-HDAC4/5 axis restricts MuERVL-marked 2-cell-like state in embryonic stem cells.","date":"2022","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36150380","citation_count":10,"is_preprint":false},{"pmid":"26547690","id":"PMC_26547690","title":"Design and synthesis of an in vivo-efficacious PIM3 kinase inhibitor as a candidate anti-pancreatic cancer agent.","date":"2015","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/26547690","citation_count":10,"is_preprint":false},{"pmid":"28775772","id":"PMC_28775772","title":"Pim-3 Regulates Stemness of Pancreatic Cancer Cells via Activating STAT3 Signaling Pathway.","date":"2017","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28775772","citation_count":10,"is_preprint":false},{"pmid":"38128397","id":"PMC_38128397","title":"Corynoline inhibits esophageal squamous cell carcinoma growth via targeting Pim-3.","date":"2023","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38128397","citation_count":8,"is_preprint":false},{"pmid":"29170467","id":"PMC_29170467","title":"mTORC1 suppresses PIM3 expression via miR-33 encoded by the SREBP loci.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29170467","citation_count":7,"is_preprint":false},{"pmid":"32504181","id":"PMC_32504181","title":"High Expression of NEK2 and PIM1, but Not PIM3, Is Linked to an Aggressive Phenotype of Bronchopulmonary Neuroendocrine Neoplasms.","date":"2020","source":"Endocrine pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32504181","citation_count":7,"is_preprint":false},{"pmid":"26269675","id":"PMC_26269675","title":"Overexpression of pim-3 and protective role in lipopolysaccharide-stimulated hepatic stellate cells.","date":"2015","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/26269675","citation_count":7,"is_preprint":false},{"pmid":"31882428","id":"PMC_31882428","title":"Effect of Pim-3 Downregulation on Proliferation and Apoptosis in Lung Adenocarcinoma A549 Cells.","date":"2019","source":"Annals of clinical and laboratory science","url":"https://pubmed.ncbi.nlm.nih.gov/31882428","citation_count":7,"is_preprint":false},{"pmid":"38002822","id":"PMC_38002822","title":"Predictive Value of PRISM-4, PIM-3, CRP, Albumin, CRP/Albumin Ratio and Lactate in Critically Ill Children.","date":"2023","source":"Children (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/38002822","citation_count":7,"is_preprint":false},{"pmid":"26529487","id":"PMC_26529487","title":"Binding site identification and role of permanent water molecule of PIM-3 kinase: A molecular dynamics study.","date":"2015","source":"Journal of molecular graphics & modelling","url":"https://pubmed.ncbi.nlm.nih.gov/26529487","citation_count":7,"is_preprint":false},{"pmid":"28833639","id":"PMC_28833639","title":"Expression and significance of Pim-3 kinase in adult T-cell leukemia.","date":"2017","source":"European journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/28833639","citation_count":6,"is_preprint":false},{"pmid":"34468207","id":"PMC_34468207","title":"LncRNA RGMB-AS1 facilitates pancreatic cancer cell proliferation and migration but inhibits cell apoptosis via miR-574-3p/PIM3 axis.","date":"2021","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/34468207","citation_count":6,"is_preprint":false},{"pmid":"31777546","id":"PMC_31777546","title":"Pim-3 alleviates lipopolysaccharide-stimulated AR42J pancreatic acinar cell injury via improving the inflammatory microenvironment.","date":"2019","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31777546","citation_count":6,"is_preprint":false},{"pmid":"24600488","id":"PMC_24600488","title":"Serine threonine kinase Pim-3 regulates STAT3 pathway to inhibit proliferation of human liver cancers.","date":"2014","source":"International journal of clinical and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24600488","citation_count":6,"is_preprint":false},{"pmid":"28214201","id":"PMC_28214201","title":"Up-regulation of Pim-3 in Chronic Obstructive Pulmonary Disease (COPD) patients and its potential therapeutic role in COPD rat modeling.","date":"2017","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/28214201","citation_count":6,"is_preprint":false},{"pmid":"39627185","id":"PMC_39627185","title":"Endothelial Pim3 kinase protects the vascular barrier during lung metastasis.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39627185","citation_count":5,"is_preprint":false},{"pmid":"38148455","id":"PMC_38148455","title":"PIM3 regulates myocardial ischemia/reperfusion injury via ferroptosis.","date":"2023","source":"Genes & genomics","url":"https://pubmed.ncbi.nlm.nih.gov/38148455","citation_count":5,"is_preprint":false},{"pmid":"36315303","id":"PMC_36315303","title":"PIM3 kinase promotes tumor metastasis in hepatoblastoma by upregulating cell surface expression of chemokine receptor cxcr4.","date":"2022","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/36315303","citation_count":5,"is_preprint":false},{"pmid":"31628693","id":"PMC_31628693","title":"Downregulation of microRNA-124 prevents the development of acute liver failure through the upregulation of PIM-3.","date":"2019","source":"Experimental physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31628693","citation_count":5,"is_preprint":false},{"pmid":"31397090","id":"PMC_31397090","title":"The serine-threonine kinase PIM3 is an aldosterone-regulated protein in the distal nephron.","date":"2019","source":"Physiological reports","url":"https://pubmed.ncbi.nlm.nih.gov/31397090","citation_count":4,"is_preprint":false},{"pmid":"41199316","id":"PMC_41199316","title":"Metabolic reprogramming through PIM3 inhibition reverses hypoxia-induced CAR-T cell dysfunction in solid tumors.","date":"2025","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41199316","citation_count":4,"is_preprint":false},{"pmid":"35338769","id":"PMC_35338769","title":"Long non-coding RNA long intergenic non-protein coding RNA 1232 promotes cell proliferation, migration and invasion in bladder cancer via modulating miR-370-5p/PIM3 axis.","date":"2022","source":"Journal of tissue engineering and regenerative medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35338769","citation_count":4,"is_preprint":false},{"pmid":"35845311","id":"PMC_35845311","title":"Multi-stage analysis of FOXM1, PYROXD1, hTERT, PPARA, PIM3, BMI1 and MCTP1 expression patterns in colorectal cancer.","date":"2022","source":"Gastroenterology and hepatology from bed to bench","url":"https://pubmed.ncbi.nlm.nih.gov/35845311","citation_count":4,"is_preprint":false},{"pmid":"35722357","id":"PMC_35722357","title":"Long non-coding RNA (FALEC) promotes malignant behaviors of gastric cancer cells by regulating miR-203b/PIM3 axis.","date":"2022","source":"Annals of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35722357","citation_count":4,"is_preprint":false},{"pmid":"40189183","id":"PMC_40189183","title":"ETS1 modulates ferroptosis to affect the process of myocardial ischemia-reperfusion injury via PIM3.","date":"2025","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/40189183","citation_count":4,"is_preprint":false},{"pmid":"39850120","id":"PMC_39850120","title":"Pim3 up-regulation by YY1 contributes to diabetes-induced cardiac hypertrophy and heart failure.","date":"2025","source":"Iranian journal of basic medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39850120","citation_count":3,"is_preprint":false},{"pmid":"39507762","id":"PMC_39507762","title":"Low miR-936-mediated upregulation of Pim-3 drives sorafenib resistance in liver cancer through ferroptosis inhibition by activating the ANKRD18A/Src/NRF2 pathway.","date":"2024","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/39507762","citation_count":3,"is_preprint":false},{"pmid":"18261321","id":"PMC_18261321","title":"[Protective role of Pim-3 gene in intestinal mucosa damaged by burn or lipopolysaccharide].","date":"2007","source":"Zhonghua yi xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/18261321","citation_count":3,"is_preprint":false},{"pmid":"37248373","id":"PMC_37248373","title":"LncRNA SNHG1 Accelerates Cell Proliferation, Migration, and Invasion of Hepatoblastoma Through Mediating miR-6838-5p/PIM3/RhoA Axis.","date":"2023","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37248373","citation_count":1,"is_preprint":false},{"pmid":"38199328","id":"PMC_38199328","title":"Identification of 4-(6-((2-methoxyphenyl)amino)pyrazin-2-yl)benzoic acids as CSNK2A inhibitors with antiviral activity and improved selectivity over PIM3.","date":"2024","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/38199328","citation_count":1,"is_preprint":false},{"pmid":"27150984","id":"PMC_27150984","title":"[Expression and Significance of Pim-3 Gene in Acute Myeloid Leukemia].","date":"2016","source":"Zhongguo shi yan xue ye xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/27150984","citation_count":1,"is_preprint":false},{"pmid":"38106118","id":"PMC_38106118","title":"Identification of 4-(6-((2-methoxyphenyl)amino)pyrazin-2-yl)benzoic acids as CSNK2A inhibitors with antiviral activity and improved selectivity over PIM3.","date":"2023","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38106118","citation_count":1,"is_preprint":false},{"pmid":"30481923","id":"PMC_30481923","title":"[Effects of endotoxin/lipopolysaccharide on early apoptosis of human neutrophil through PIM3].","date":"2018","source":"Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns","url":"https://pubmed.ncbi.nlm.nih.gov/30481923","citation_count":1,"is_preprint":false},{"pmid":"8666412","id":"PMC_8666412","title":"Low frequency of PIM3 gene in patients with monoclonal gammopathies.","date":"1996","source":"Human heredity","url":"https://pubmed.ncbi.nlm.nih.gov/8666412","citation_count":1,"is_preprint":false},{"pmid":"23207234","id":"PMC_23207234","title":"[Inhibitive mechanisms of Pim-3 affecting fulminant hepatic apoptosis].","date":"2012","source":"Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/23207234","citation_count":1,"is_preprint":false},{"pmid":"41090348","id":"PMC_41090348","title":"PIM3-mediated phosphorylation stabilizes myeloid leukemia factor 2 to promote metastasis in osteosarcoma.","date":"2025","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/41090348","citation_count":0,"is_preprint":false},{"pmid":"41478528","id":"PMC_41478528","title":"PIM3 enhances nucleus pulposus cell function and extracellular matrix integrity via kinase-dependent activation of the Akt/mTOR signaling axis in intervertebral disc degeneration.","date":"2025","source":"Translational research : the journal of laboratory and clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41478528","citation_count":0,"is_preprint":false},{"pmid":"18067836","id":"PMC_18067836","title":"[Construction of a recombinant Pim3-expressing plasmid and expression and activity thereof: experiment with rats].","date":"2007","source":"Zhonghua yi xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/18067836","citation_count":0,"is_preprint":false},{"pmid":"42201413","id":"PMC_42201413","title":"Berberine impedes the DNA damage repair to inhibit colorectal cancer by regulating the SOX17/TCF4/PIM3 axis.","date":"2026","source":"Molecular genetics and genomics : MGG","url":"https://pubmed.ncbi.nlm.nih.gov/42201413","citation_count":0,"is_preprint":false},{"pmid":"42106777","id":"PMC_42106777","title":"miR-1307-5p mediates endothelial dysfunction and inflammation induced by acute coronary syndrome by targeting PIM3.","date":"2026","source":"Journal of cardiothoracic surgery","url":"https://pubmed.ncbi.nlm.nih.gov/42106777","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.10.22.683941","title":"Identification and Validation of an inhibitor of the protein kinases PIM and DYRK","date":"2025-10-22","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.22.683941","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":46251,"output_tokens":9070,"usd":0.137402,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19122,"output_tokens":5566,"usd":0.11738,"stage2_stop_reason":"end_turn"},"total_usd":0.254782,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2006,\n      \"finding\": \"PIM3 serine/threonine kinase phosphorylates the pro-apoptotic protein BAD at Ser112 (but not Ser136) in human pancreatic cancer cells, inactivating BAD and preventing apoptosis; PIM3 knockdown reduced pBAD(Ser112) and Bcl-XL expression and promoted apoptosis.\",\n      \"method\": \"shRNA knockdown, Western blot for pBAD(Ser112) and pBAD(Ser136), flow cytometry for apoptosis\",\n      \"journal\": \"Cancer Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — replicated across multiple cancer types (pancreas, colon, liver) by multiple labs using KD with defined molecular readout (pBAD Ser112)\",\n      \"pmids\": [\"16818649\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PIM3 phosphorylates BAD at Ser112 in human colon cancer cells, inactivating BAD to prevent apoptosis; PIM3 knockdown specifically abrogated Ser112 phosphorylation and promoted apoptosis.\",\n      \"method\": \"shRNA knockdown, Western blot, co-localization by immunohistochemistry\",\n      \"journal\": \"Cancer Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — independently replicated in colon cancer confirming the pancreatic cancer findings, reciprocal IHC co-localization\",\n      \"pmids\": [\"17270021\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PIM3 is aberrantly expressed in human hepatocellular carcinoma cell lines but not normal liver; RNA interference-mediated ablation of PIM3 attenuated cell proliferation and enhanced apoptosis in hepatoma cell lines.\",\n      \"method\": \"RNA interference, cell proliferation assay, apoptosis assay; fluorescent differential display to identify gene\",\n      \"journal\": \"International Journal of Cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KD with defined cellular phenotype in a single lab, two orthogonal readouts (proliferation + apoptosis)\",\n      \"pmids\": [\"15540201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PIM3 is a direct transcriptional target of EWS/ETS oncoproteins; forced expression of PIM3 promotes anchorage-independent growth, and co-expression of a kinase-deficient PIM3 mutant attenuated EWS/FLI1-mediated tumorigenesis in immunodeficient mice.\",\n      \"method\": \"Microarray expression analysis, forced expression assay, kinase-dead mutant co-expression, in vivo tumorigenesis assay\",\n      \"journal\": \"Molecular and Cellular Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — kinase-dead mutant rescue + in vivo functional validation in one study\",\n      \"pmids\": [\"12748291\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The transcription factor Ets-1 binds the PIM3 promoter (between -249 and -183 bp) and drives constitutive PIM3 expression in human pancreatic cancer cells; mutation of the Ets-1 binding site (-216 to -211 bp) reduced promoter activity, and dominant-negative Ets-1 or Ets-1 siRNA reduced PIM3 expression, pBAD(Ser112) levels, and induced apoptosis—effects reversed by PIM3 cDNA re-introduction.\",\n      \"method\": \"Luciferase reporter with deletion mutants, chromatin immunoprecipitation (ChIP), dominant-negative transfection, Ets-1 siRNA, rescue experiment with PIM3 cDNA\",\n      \"journal\": \"Cancer Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — ChIP + reporter assay + mutagenesis + functional rescue in one study\",\n      \"pmids\": [\"19154409\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PIM3 (along with PIM1) phosphorylates the KSHV latency-associated nuclear antigen LANA on serine residues 205 and 206, counteracting LANA-mediated repression of lytic gene transcription and thereby promoting KSHV reactivation from latency.\",\n      \"method\": \"Overexpression of Pim kinases, identification of phosphorylation sites on LANA, KSHV reactivation assays in naturally infected cells\",\n      \"journal\": \"PLoS Pathogens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — specific phosphorylation sites identified with functional validation, single lab\",\n      \"pmids\": [\"19266083\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PIM3 expression in mouse embryonic stem cells is upregulated by LIF/gp130/STAT3 signaling; overexpression of PIM3 enhanced ES cell self-renewal and resistance to LIF withdrawal, while knockdown increased spontaneous differentiation and apoptosis.\",\n      \"method\": \"Granulocyte colony-stimulating factor:gp130 chimeric receptor + hormone-dependent STAT3-ER system, clonal self-renewal assay, shRNA knockdown\",\n      \"journal\": \"Stem Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean gain- and loss-of-function with defined phenotypic readout, single lab\",\n      \"pmids\": [\"17717068\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PIM3 liver-specific transgenic mice do not develop spontaneous HCC but show accelerated hepatocyte cell cycle progression; upon diethylnitrosamine (DEN) treatment, these mice develop HCC with higher incidence (80% vs 40%) and heavier tumor burden, demonstrating PIM3 acts as a tumor promoter rather than initiator.\",\n      \"method\": \"Liver-specific transgenic mouse model, DEN-induced hepatocarcinogenesis, histological analysis, immunohistochemistry for proliferating cells and CD31+ vascular areas\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo transgenic model with clear mechanistic distinction (promoter vs. initiator), multiple readouts\",\n      \"pmids\": [\"20101231\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PIM3 is expressed at high levels in endothelial cells where it localizes to lamellipodia and co-localizes with focal adhesion kinase (FAK); treatment with the actin polymerization inhibitor cytochalasin D dispersed PIM3 from lamellipodia; siRNA-mediated PIM3 knockdown impaired EC spreading, migration, proliferation, and tube-like structure formation in Matrigel assay.\",\n      \"method\": \"Immunofluorescence localization, co-localization with FAK, cytochalasin D treatment, siRNA knockdown, Matrigel tube formation assay\",\n      \"journal\": \"Journal of Cellular Physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — localization experiment tied to functional consequence, multiple cellular readouts\",\n      \"pmids\": [\"19229879\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Translationally controlled tumor protein (TCTP) interacts with PIM3 through PIM3's C-terminal region and TCTP's N-terminal region; TCTP overexpression increases PIM3 protein levels dose-dependently, while TCTP knockdown reduces PIM3 protein (but not mRNA) via the ubiquitin-proteasome degradation system, establishing TCTP as a regulator of PIM3 protein stability.\",\n      \"method\": \"Yeast two-hybrid screen, co-immunoprecipitation, domain mapping, RNAi-mediated knockdown, proteasome inhibitor experiments, in vitro and in vivo tumor growth assays\",\n      \"journal\": \"Molecular Cancer Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — yeast two-hybrid + Co-IP + domain mapping + proteasomal mechanism + in vivo validation in one study\",\n      \"pmids\": [\"24165482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PIM3 is a direct transcriptional target of c-Myc, which binds to conserved E-boxes in the PIM3 gene; lymphomas in Myc-transgenic mice and Burkitt lymphoma cell lines exhibit elevated PIM3 levels; pan-PIM kinase inhibition in Myc-induced lymphoma causes caspase-independent cell death.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) for c-Myc binding to PIM3 E-boxes, pharmacological Pim kinase inhibitor, cell death assay\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirms direct target binding, functional pharmacological inhibition, single lab\",\n      \"pmids\": [\"21646687\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PIM3 negatively regulates glucose-stimulated insulin secretion in pancreatic β-cells; Pim3-/- mice show enhanced second-phase insulin secretion, increased glucose tolerance, and increased insulin sensitivity; PIM3 physically interacts with SOCS6, whose levels are reduced in Pim3-/- islets; overexpression of SOCS6 inhibits glucose-induced ERK1/2 activation, suggesting PIM3 suppresses insulin secretion by inhibiting ERK1/2 through SOCS6.\",\n      \"method\": \"Pim3 knockout mouse, glucose-stimulated insulin secretion assay in MIN6 cells and isolated islets, in vivo glucose tolerance test, ERK1/2 phosphorylation assay, co-immunoprecipitation for SOCS6, SOCS6 overexpression\",\n      \"journal\": \"Islets\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — knockout mouse + in vitro + in vivo + Co-IP + epistasis (SOCS6 OE rescuing ERK activity) in one study\",\n      \"pmids\": [\"21099329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PIM3 kinase activity promotes pancreatic cancer vasculogenesis and tumor growth; wild-type PIM3 overexpression increased Bad(Ser112) phosphorylation and proliferation, while kinase-dead PIM3 (K69M mutant) reduced these effects; PIM3 upregulated pSTAT3(Tyr705), pSurvivin(Thr34), and angiogenic factors including VEGF, HGF, EGF, and FGF-2 in a kinase-dependent manner.\",\n      \"method\": \"Stable overexpression of wild-type vs. kinase-dead K69M-PIM3 mutant, shRNA knockdown, xenograft mouse model, Western blot, histological analysis of CD31+ vascular areas\",\n      \"journal\": \"Oncology Reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — kinase-dead mutant comparison establishes kinase-dependence with multiple downstream readouts in vitro and in vivo\",\n      \"pmids\": [\"24789328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"miR-33a directly targets the 3'-UTR of PIM3 mRNA to suppress its expression in pancreatic cancer; PIM3 suppression by miR-33a leads to downregulation of the AKT/GSK-3β/β-catenin pathway, inhibiting tumor growth and increasing gemcitabine chemosensitivity.\",\n      \"method\": \"Dual luciferase reporter assay for miR-33a targeting PIM3 3'-UTR, Western blot for downstream signaling, in vitro and in vivo proliferation/chemosensitivity assays\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — luciferase reporter confirms direct targeting, pathway effects measured, single lab\",\n      \"pmids\": [\"25971209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"mTORC1 suppresses PIM3 expression via SREBP transcription factors and miR-33 (an intronic microRNA encoded within the SREBP loci); rapamycin inhibition of mTORC1 induces PIM3 transcript and protein levels; this pathway operates in cells with TSC loss-of-function and in mouse liver upon feeding.\",\n      \"method\": \"Rapamycin treatment, TSC knockout cells, SREBP manipulation, miR-33 expression analysis, in vivo mouse liver feeding experiments\",\n      \"journal\": \"Scientific Reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple genetic contexts tested, in vivo validation, single lab\",\n      \"pmids\": [\"29167471\", \"29170467\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PIM3 promotes melanoma cell migration and invasion by promoting STAT3 phosphorylation, which induces expression of EMT-related transcription factors Slug, Snail, and ZEB1; PIM3 knockdown inhibited B16F10 cell migration in vitro and reduced pulmonary metastasis in a tumor-bearing mouse model.\",\n      \"method\": \"shRNA knockdown, in vitro migration/invasion assay, in vivo metastasis mouse model, Western blot for STAT3 phosphorylation and EMT markers\",\n      \"journal\": \"Cancer Biology & Therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — KD with in vivo validation, pathway placement via STAT3/EMT markers, single lab\",\n      \"pmids\": [\"29370558\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PIM3 contributes to radioresistance in pancreatic cancer cells by attenuating G2/M phase cell cycle arrest and DNA damage response; PIM3 silencing elevated phosphorylation of histone H2AX (γH2AX, a DNA double-strand break marker) and decreased ATM kinase activation, enhancing radiosensitivity in vitro and in vivo.\",\n      \"method\": \"Stable PIM3 overexpression and shRNA knockdown, γH2AX and ATM phosphorylation by Western blot, cell cycle analysis, xenograft in vivo radiosensitivity assay\",\n      \"journal\": \"Biochemical and Biophysical Research Communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with defined molecular readouts and in vivo validation, single lab\",\n      \"pmids\": [\"27016481\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PIM3 expression in cardiomyocytes is upregulated by anoxic preconditioning via a p38 MAPK signaling pathway; transfection of PIM3 into rat cardiomyocytes attenuated anoxia/reoxygenation injury; inhibition of p38 MAPK by SB203580 abolished both PIM3 upregulation and the cardioprotective effect.\",\n      \"method\": \"PIM3 expression vector transfection into rat cardiomyocytes, p38 MAPK inhibitor (SB203580), anoxia/reoxygenation model, cell viability and apoptosis assays\",\n      \"journal\": \"International Journal of Biochemistry & Cell Biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — pharmacological epistasis + gain-of-function with functional readout, single lab\",\n      \"pmids\": [\"19505587\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PIM3 overexpression promotes liver cancer cell migration by activating RhoA GTPase through phosphorylation of multiple Rho GTPase modulators, leading to cytoskeletal rearrangements; quantitative phosphoproteomics revealed PIM3-induced phosphorylation changes across signal transduction, cell cycle, and apoptosis networks.\",\n      \"method\": \"Quantitative proteomics and phosphoproteomics in PIM3-overexpressing liver cancer cells, RhoA activity assay, cytoskeletal analysis\",\n      \"journal\": \"Journal of Proteome Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phosphoproteomics + functional validation of RhoA activation + cytoskeletal readout, single lab\",\n      \"pmids\": [\"31994402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PIM3 overexpression promotes AML cell migration via CXCR4; PIM3-overexpressing AML cells exhibited increased CXCR4 phosphorylation at Ser339, and phosphorylated CXCR4 physically interacted with PIM3 by co-immunoprecipitation; PIM3 also phosphorylated BAD at Ser112 to protect against apoptosis.\",\n      \"method\": \"Co-immunoprecipitation of PIM3 and pCXCR4(Ser339), cell migration assay, Western blot for pBAD(Ser112), flow cytometry\",\n      \"journal\": \"OncoTargets and Therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — Co-IP confirms PIM3/pCXCR4 interaction, functional migration assay, single lab\",\n      \"pmids\": [\"32764981\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PIM3 suppresses the totipotent 2-cell-like state in embryonic stem cells via an AMPK-HDAC4/5 axis; loss of PIM3 increases AMPK phosphorylation, causing HDAC4/5 nuclear export, which reduces H3K9me1/2 and increases H3K9ac on MuERVL retroviral elements, thereby activating 2-cell genes.\",\n      \"method\": \"PIM3 knockout ESCs, AMPK phosphorylation assays, HDAC4/5 nuclear/cytoplasmic fractionation, chromatin modification (H3K9ac, H3K9me1/2) analysis at MuERVL loci, pharmacological PIM3 inhibition\",\n      \"journal\": \"Stem Cell Reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO + epistasis through AMPK/HDAC axis + chromatin readout, single lab\",\n      \"pmids\": [\"36150380\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In adult T-cell leukemia, viral Tax protein induces PIM3 expression through NF-κB signaling; PIM3 knockdown inhibited growth of HTLV-1-infected T cells; PIM1/3 kinase inhibitor NJC97-NH induced G2/M arrest with downregulation of cyclin A and cyclin B1, and apoptosis with downregulation of XIAP and Mcl-1 via inhibition of NF-κB (decreased IκBα and RelA phosphorylation).\",\n      \"method\": \"siRNA knockdown of PIM3 and RelA, pharmacological Pim inhibitor, EMSA for NF-κB DNA binding, Western blot, cell cycle and apoptosis analysis\",\n      \"journal\": \"European Journal of Haematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — epistasis (Tax→NF-κB→PIM3) with multiple readouts, EMSA confirms NF-κB binding, single lab\",\n      \"pmids\": [\"28833639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PIM3 maintains stemness of pancreatic cancer cells by activating the STAT3 signaling pathway; PIM3 silencing decreased proportions of CD24+ESA+ cancer stem-like cells and reduced stemness-associated transcription factors including STAT3 phosphorylation; restoration of STAT3 activity rescued the stem cell-like phenotype in PIM3-silenced cells.\",\n      \"method\": \"PIM3 siRNA knockdown, STAT3 phosphorylation/transcriptional activity assay, CD24+ESA+ cell population flow cytometry, STAT3 rescue experiment\",\n      \"journal\": \"Journal of Cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — KD + rescue epistasis through STAT3, single lab\",\n      \"pmids\": [\"28775772\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Aldosterone stimulates PIM3 expression in the distal nephron in vitro (mCCDcl1 cells), ex vivo (mouse kidney slices), and in vivo; Pim3-/- mice display upregulated RAAS (elevated aldosterone and plasma renin activity) but no overt salt-losing phenotype, potentially compensated by upregulation of PIM1 and PIM2 in the kidney.\",\n      \"method\": \"Germline Pim3 knockout mouse, aldosterone treatment in multiple systems, electrolyte/blood pressure measurements, expression analysis of PIM family members and Na+ transporters\",\n      \"journal\": \"Physiological Reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockout mouse model with in vitro/ex vivo/in vivo corroboration, single lab\",\n      \"pmids\": [\"31397090\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PIM3 kinase promotes hepatoblastoma metastasis by upregulating phosphorylation and cell surface expression of CXCR4; PIM3 knockout by CRISPR/Cas9 impaired lung metastasis formation in vivo; CXCR4 blockade with AMD3100 decreased the metastatic phenotype of PIM3-overexpressing cells.\",\n      \"method\": \"CRISPR/Cas9 PIM3 knockout, stable PIM3 overexpression, tail vein injection metastasis model, AMD3100 CXCR4 blockade, CXCR4 surface expression analysis\",\n      \"journal\": \"Clinical & Experimental Metastasis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CRISPR KO + OE + pharmacological blockade + in vivo metastasis model + mechanistic rescue, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"36315303\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CRISPR/Cas9-mediated PIM3 knockout in hepatoblastoma cells decreased proliferation, viability, motility, tumor growth in xenograft model, and cancer cell stemness (tumorsphere formation, CD133 expression, stemness marker mRNAs); reintroduction of PIM3 rescued the malignant phenotype.\",\n      \"method\": \"CRISPR/Cas9 dual gRNA knockout, xenograft murine model, RNA sequencing, tumorsphere assay, CD133 flow cytometry, PIM3 rescue experiment\",\n      \"journal\": \"Cancer Gene Therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CRISPR KO with genetic rescue + in vivo + transcriptomic analysis, multiple orthogonal readouts\",\n      \"pmids\": [\"33864024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PIM3-mediated phosphorylation of myeloid leukemia factor 2 (MLF2) at Ser65 enhances MLF2 stability by promoting its interaction with the deubiquitinase USP21, thereby protecting MLF2 from STUB1-mediated ubiquitination and proteasomal degradation at Lys119; MLF2 promotes osteosarcoma metastasis by disrupting the BiP-IRE1α interaction, activating the IRE1α/XBP1-S-MMP9 axis.\",\n      \"method\": \"In vivo CRISPR activation screen combined with STUB1 interactome, phosphorylation site mapping, ubiquitination assays, Co-IP for USP21/MLF2/PIM3 interactions, xenograft metastasis model\",\n      \"journal\": \"Journal of Clinical Investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — phosphorylation site identification + ubiquitination mechanism + protein-protein interaction mapping + in vivo validation in one rigorous study\",\n      \"pmids\": [\"41090348\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PIM3 inhibition increases vascular leakage and metastatic colonization in the lung; endothelial PIM3 (activated by JAK-STAT) protects the vascular barrier by maintaining junctional cadherin-5 and catenins α, β, and δ at endothelial cell junctions; PIM inhibition impairs the EC barrier.\",\n      \"method\": \"scRNA-seq of lung ECs in metastasis models, pharmacological PIM inhibition, vascular permeability assay, junctional protein expression analysis, spontaneous metastasis mouse models\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — scRNA-seq identification + functional inhibition in vivo + defined molecular mechanism (junctional proteins), replicated in multiple metastasis models\",\n      \"pmids\": [\"39627185\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PIM3 physically interacts with and activates the Akt signaling pathway in nucleus pulposus cells to regulate downstream mTOR and FoxO1, modulating cell viability and senescence in a kinase-activity-dependent manner; AAV-mediated PIM3 overexpression in an IDD rat model improved ECM integrity and reduced senescence.\",\n      \"method\": \"Co-immunoprecipitation of PIM3 and Akt, knockdown and overexpression including kinase-dead mutant, Akt/mTOR/FoxO1 phosphorylation assays, AAV in vivo model\",\n      \"journal\": \"Translational Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP + kinase-dead comparison + in vivo validation, single lab\",\n      \"pmids\": [\"41478528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PIM3 phosphorylates MAPK1 (ERK2) at T185 and Y187 in esophageal squamous cell carcinoma cells, promoting cell proliferation and tumor development; corynoline directly binds PIM3 and inhibits its kinase activity; PIM3 deletion induced apoptosis with upregulated cleaved caspase-9 and reduced BAD phosphorylation at S112.\",\n      \"method\": \"Pull-down assay, cellular thermal shift assay (CETSA), kinase assay, Western blot for pMAPK1(T185/Y187) and pBAD(S112), patient-derived xenograft model\",\n      \"journal\": \"Phytomedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — kinase assay + CETSA + PDX model identifies new substrate MAPK1, single lab\",\n      \"pmids\": [\"38128397\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PIM3 is upregulated by the transcription factor YY1, which translocates from the cytoplasm to the nucleus under hyperglycemia and binds the PIM3 promoter, enhancing PIM3 transcriptional activity; PIM3 or YY1 knockdown reduced cardiac hypertrophy markers and attenuated diabetic cardiac dysfunction in mice.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) and luciferase reporter assay for YY1-PIM3 promoter interaction, siRNA and lentivirus-mediated knockdown, streptozotocin diabetic mouse model, echocardiography\",\n      \"journal\": \"Iranian Journal of Basic Medical Sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP + reporter assay + in vivo mouse model, single lab\",\n      \"pmids\": [\"39850120\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"The compound CSH-4044 (isolated from fermented wheat germ extract) is an ATP-competitive inhibitor of PIM kinases including PIM3; it suppresses PIM3-driven BAD phosphorylation in pancreatic cancer cells; co-crystal structure of CSH-4044 with PIM1 revealed critical hydrophobic and hydrogen-bonding interactions at the ATP binding site.\",\n      \"method\": \"X-ray co-crystallography of PIM1-CSH-4044, kinase profiling, BAD phosphorylation assay in pancreatic cancer cells\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — crystal structure + kinase assay + cellular readout in single preprint, not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2025.10.22.683941\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Knockdown of PIM3 inhibits ferroptosis in myocardial I/R injury, alleviating myocardial damage; PIM3 expression is increased by myocardial I/R or OGD/R, and PIM3 silencing reduced ROS, MDA, and iron content while increasing SOD, GPX4, and FTH1.\",\n      \"method\": \"In vivo rat myocardial I/R model, H9c2 OGD/R cell model, siRNA knockdown, Western blot for ferroptosis markers (TfR1, FTH1, GPX4), ROS/MDA/SOD assays\",\n      \"journal\": \"Genes & Genomics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — KD with phenotypic readout but no direct mechanistic pathway placement for PIM3 in ferroptosis, single lab\",\n      \"pmids\": [\"38148455\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ETS1 transcription factor promotes PIM3 expression under OGD/R conditions (simulating myocardial ischemia-reperfusion injury) by binding the PIM3 promoter; ETS1 knockdown suppressed ferroptosis and myocardial injury through reducing PIM3 expression; the ETS1→PIM3 axis exacerbates ferroptosis in cardiomyocytes.\",\n      \"method\": \"OGD/R H9C2 cell model, mouse MIRI model, ETS1 knockdown, Western blot for ETS1/PIM3/ferroptosis markers (GPX4, SLC7A11, FTH1), immunofluorescence\",\n      \"journal\": \"Experimental Cell Research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — epistasis implied but ChIP/promoter binding for ETS1-PIM3 not explicitly described in abstract, single lab\",\n      \"pmids\": [\"40189183\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Cholesterol promotes CRC cell proliferation partly through the miR-33a/PIM3 axis; PIM3 was identified as a direct target of miR-33a by dual luciferase reporter assay; PIM3 modulates CRC cell proliferation and apoptosis by phosphorylating p27, p21, and BAD.\",\n      \"method\": \"Dual luciferase reporter assay, Western blot for pBad/pp27/pp21, CCK-8 and flow cytometry with cholesterol treatment and miR-33a manipulation\",\n      \"journal\": \"Biochemical and Biophysical Research Communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — direct targeting confirmed by luciferase, but phosphorylation of p27 and p21 by PIM3 not directly demonstrated by kinase assay, single lab\",\n      \"pmids\": [\"30827510\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PIM3 is a constitutively active serine/threonine kinase whose principal established substrates include BAD (phosphorylated at Ser112 to suppress apoptosis), LANA (phosphorylated at Ser205/206 to enable KSHV reactivation), MLF2 (phosphorylated at Ser65 to stabilize it via USP21 recruitment), CXCR4 (phosphorylated at Ser339 to promote cell migration), and MAPK1/ERK2 (phosphorylated at T185/Y187 to drive proliferation); PIM3 expression is transcriptionally regulated by Ets-1, c-Myc, STAT3, YY1, and EWS/ETS fusion proteins, post-translationally stabilized by TCTP (which prevents ubiquitin-proteasomal degradation), and suppressed post-transcriptionally by mTORC1 via SREBP-encoded miR-33; PIM3 localizes to lamellipodia in endothelial cells (dependent on actin polymerization) and at endothelial junctions where it maintains cadherin-5 and catenin expression to protect vascular barrier integrity; in β-cells PIM3 negatively regulates glucose-stimulated insulin secretion by suppressing ERK1/2 activation through SOCS6; and in embryonic stem cells PIM3 represses totipotency by activating AMPK-HDAC4/5-mediated histone methylation at MuERVL loci.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"PIM3 is a constitutively active serine/threonine kinase that functions broadly as a pro-survival, pro-proliferative, and pro-migratory effector across cancer, vascular, endocrine, and stem-cell contexts [#0, #12]. Its best-characterized substrate is the pro-apoptotic protein BAD, which PIM3 phosphorylates specifically at Ser112 (not Ser136) to inactivate it and suppress apoptosis—an activity replicated across pancreatic, colon, hepatoma, and leukemic cells [#0, #1, #19]. Beyond BAD, PIM3 phosphorylates a defined substrate set that explains its diverse phenotypes: MAPK1/ERK2 at T185/Y187 to drive proliferation [#29], CXCR4 at Ser339 to promote migration and metastatic colonization [#19, #24], the KSHV antigen LANA at Ser205/206 to enable viral reactivation [#5], and MLF2 at Ser65 to stabilize it via USP21-mediated protection from STUB1 ubiquitination [#26]. Its kinase activity is required for these outputs, as kinase-dead mutants (e.g., K69M) abolish BAD phosphorylation, proliferation, and tumor-promoting vasculogenesis [#3, #12]. PIM3 expression is transcriptionally driven by multiple oncogenic inputs—EWS/ETS fusions [#3], Ets-1 [#4], c-Myc [#10], Tax/NF-κB [#21], and YY1 [#30]—and is post-translationally stabilized by TCTP, which binds PIM3's C-terminus to block its ubiquitin-proteasomal degradation [#9]; conversely, mTORC1 represses PIM3 via SREBP-encoded miR-33 [#14]. In normal physiology, PIM3 negatively regulates glucose-stimulated insulin secretion in β-cells by suppressing ERK1/2 through SOCS6 [#11], protects the endothelial vascular barrier by maintaining junctional cadherin-5 and catenins [#27], and represses the totipotent 2-cell-like state in embryonic stem cells via an AMPK–HDAC4/5 axis that silences MuERVL elements [#20]. As an oncogene PIM3 acts as a tumor promoter rather than initiator, accelerating hepatocyte cell cycle progression without inducing spontaneous tumors [#7].\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"Established PIM3 as an oncogenic effector downstream of a fusion oncoprotein, answering whether its kinase activity is functionally required for transformation.\",\n      \"evidence\": \"Microarray, forced expression, kinase-dead co-expression, and in vivo tumorigenesis in immunodeficient mice for EWS/ETS-driven Ewing sarcoma\",\n      \"pmids\": [\"12748291\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify direct phosphorylation substrates\", \"Mechanism of anchorage-independent growth not resolved at the molecular level\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identified BAD Ser112 as a direct PIM3 phosphorylation target, defining the molecular basis of its anti-apoptotic activity.\",\n      \"evidence\": \"shRNA knockdown and phospho-specific Western blot in pancreatic cancer cells; replicated in colon cancer (2007)\",\n      \"pmids\": [\"16818649\", \"17270021\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Site specificity (Ser112 vs Ser136) shown by KD but not by in vitro kinase assay in original work\", \"Other pro-survival substrates not yet mapped\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Extended PIM3 substrate range beyond cancer to a viral target, showing it phosphorylates KSHV LANA at Ser205/206 to drive lytic reactivation.\",\n      \"evidence\": \"Pim kinase overexpression, phosphosite identification, and reactivation assays in naturally infected cells\",\n      \"pmids\": [\"19266083\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Redundancy with PIM1 not fully separated\", \"Physiological PIM3 levels during natural reactivation not established\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Distinguished PIM3 as a tumor promoter rather than an initiator, clarifying its causal role in hepatocarcinogenesis.\",\n      \"evidence\": \"Liver-specific transgenic mice with DEN-induced HCC and proliferation/vascular readouts\",\n      \"pmids\": [\"20101231\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct substrate driving accelerated cell cycle in vivo not identified\", \"No spontaneous tumor model\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined a non-cancer cellular role: PIM3 localizes to lamellipodia in an actin-dependent manner and is required for endothelial migration and tube formation.\",\n      \"evidence\": \"Immunofluorescence, cytochalasin D treatment, FAK co-localization, and siRNA functional assays in endothelial cells\",\n      \"pmids\": [\"19229879\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No cytoskeletal substrate identified at this stage\", \"Mechanism linking localization to migration unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Revealed how PIM3 protein levels are controlled, identifying TCTP as a stabilizer that blocks proteasomal degradation.\",\n      \"evidence\": \"Yeast two-hybrid, Co-IP, domain mapping, proteasome inhibitor experiments, and in vivo tumor growth\",\n      \"pmids\": [\"24165482\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase mediating PIM3 ubiquitination not identified\", \"Mechanism by which TCTP shields PIM3 unknown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Placed PIM3 within the c-Myc transcriptional program, identifying it as a direct Myc target and a vulnerability in Myc-driven lymphoma.\",\n      \"evidence\": \"ChIP for c-Myc at PIM3 E-boxes, pan-PIM inhibition, and cell death assays in Myc-transgenic/Burkitt models\",\n      \"pmids\": [\"21646687\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Caspase-independent death mechanism not defined\", \"PIM3-specific (vs pan-PIM) contribution not isolated\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Uncovered a normal endocrine function: PIM3 restrains glucose-stimulated insulin secretion via SOCS6-mediated ERK1/2 suppression.\",\n      \"evidence\": \"Pim3 knockout mice, GSIS assays, glucose tolerance tests, Co-IP for SOCS6, and SOCS6 overexpression epistasis\",\n      \"pmids\": [\"21099329\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct phosphorylation target linking PIM3 to SOCS6 not shown\", \"Compensation by other PIM family members not excluded\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established kinase-dependence of PIM3's pro-angiogenic and proliferative output using a kinase-dead K69M mutant.\",\n      \"evidence\": \"Wild-type vs K69M overexpression, shRNA, xenograft, and angiogenic factor profiling in pancreatic cancer\",\n      \"pmids\": [\"24789328\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether STAT3/Survivin/VEGF effects are direct substrates or downstream consequences unresolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified post-transcriptional repression of PIM3 by miR-33a and linked PIM3 to AKT/GSK-3β/β-catenin signaling and chemoresistance.\",\n      \"evidence\": \"Dual luciferase reporter, pathway Western blots, and in vivo chemosensitivity assays in pancreatic cancer\",\n      \"pmids\": [\"25971209\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct PIM3 substrate in the AKT/GSK-3β axis not identified\", \"Single regulatory miRNA tested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Connected PIM3 regulation to nutrient/growth signaling, showing mTORC1 suppresses PIM3 via SREBP and miR-33.\",\n      \"evidence\": \"Rapamycin treatment, TSC knockout cells, SREBP manipulation, and in vivo mouse liver feeding\",\n      \"pmids\": [\"29167471\", \"29170467\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of PIM3 induction under mTORC1 inhibition not fully characterized\", \"Single lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrated PIM3 supports cancer stemness through STAT3 activation in pancreatic cancer.\",\n      \"evidence\": \"siRNA knockdown, STAT3 activity assays, CD24+ESA+ flow cytometry, and STAT3 rescue\",\n      \"pmids\": [\"28775772\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether STAT3 phosphorylation is direct or indirect not established\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Extended PIM3's migratory role to melanoma metastasis via STAT3-driven EMT.\",\n      \"evidence\": \"shRNA, migration/invasion assays, in vivo metastasis model, and EMT marker Western blots\",\n      \"pmids\": [\"29370558\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct STAT3 phosphorylation by PIM3 not demonstrated by kinase assay\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Used phosphoproteomics to broaden the PIM3 signaling map and identify RhoA activation driving cytoskeletal rearrangement and migration.\",\n      \"evidence\": \"Quantitative phosphoproteomics, RhoA activity assay, and cytoskeletal analysis in liver cancer cells\",\n      \"pmids\": [\"31994402\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct Rho-modulator substrates inferred from phosphoproteomics not individually validated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified CXCR4 Ser339 as a PIM3 phosphorylation target promoting AML migration.\",\n      \"evidence\": \"Co-IP of PIM3 with pCXCR4(Ser339), migration assay, and pBAD(Ser112) Western blot\",\n      \"pmids\": [\"32764981\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct in vitro kinase assay on CXCR4 not shown\", \"Single cancer type\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Validated the PIM3-CXCR4 axis as a driver of metastasis using genetic and pharmacological loss-of-function.\",\n      \"evidence\": \"CRISPR/Cas9 knockout, overexpression, AMD3100 CXCR4 blockade, and tail-vein metastasis in hepatoblastoma\",\n      \"pmids\": [\"36315303\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether surface CXCR4 increase is solely phosphorylation-driven not isolated\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealed a developmental role: PIM3 represses the totipotent 2-cell-like state via an AMPK-HDAC4/5-MuERVL chromatin axis.\",\n      \"evidence\": \"PIM3 knockout ESCs, AMPK phosphorylation, HDAC4/5 fractionation, and chromatin modification analysis at MuERVL loci\",\n      \"pmids\": [\"36150380\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct PIM3 substrate upstream of AMPK not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified MAPK1/ERK2 (T185/Y187) as a direct PIM3 substrate driving proliferation, and a small-molecule inhibitor (corynoline).\",\n      \"evidence\": \"Pull-down, CETSA, in vitro kinase assay, and patient-derived xenograft in esophageal carcinoma\",\n      \"pmids\": [\"38128397\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Dual-residue (T/Y) phosphorylation mechanism by a Ser/Thr kinase not mechanistically explained\", \"Single lab\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Established a protective vascular function distinct from its oncogenic roles: endothelial PIM3 maintains junctional integrity to limit metastatic colonization.\",\n      \"evidence\": \"scRNA-seq of lung endothelial cells, pharmacological PIM inhibition, permeability assays, and multiple metastasis models\",\n      \"pmids\": [\"39627185\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct junctional-protein substrate not identified\", \"PIM3-specific vs pan-PIM contribution not separated pharmacologically\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Defined a stabilization mechanism whereby PIM3 phosphorylates MLF2 at Ser65 to recruit USP21 and protect it from STUB1-mediated degradation, driving osteosarcoma metastasis.\",\n      \"evidence\": \"In vivo CRISPR activation screen, phosphosite mapping, ubiquitination assays, Co-IP, and xenograft metastasis\",\n      \"pmids\": [\"41090348\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality of phospho-stabilization mechanism to other substrates unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How PIM3 achieves overlapping but context-specific substrate selection, and whether its protective (endothelial barrier, β-cell) versus oncogenic functions reflect distinct substrate pools, complexes, or localizations, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural basis for substrate selectivity established for PIM3 itself\", \"Functional redundancy with PIM1/PIM2 incompletely mapped\", \"Most disease-context substrates inferred without in vitro kinase validation\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 5, 19, 26, 29]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 12, 29]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [31]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [8, 18]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [8, 27]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [11, 22, 28, 29]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 7, 24, 26]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"BAD\", \"TCTP\", \"SOCS6\", \"CXCR4\", \"MLF2\", \"USP21\", \"AKT\", \"MAPK1\"],\n    \"other_free_text\": []\n  }\n}\n```","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}